Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Our aim was to examine the effects of GLP-1 and PYY 3–36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men. Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m 2, age 33 ± 9 yr). On separate days they received a 150-min intravenous infusion of 1) 0.8 pmol·kg−1·min−1 PYY 3–36, 2) 1.0 pmol·kg−1·min−1 GLP-1, 3) GLP-1 + PYY 3–36, or 4) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period. No effect on energy intake was found after monoinfusions of PYY 3–36 (−4.2 ± 4.8%, P = 0.8) or GLP-1 (−3.0 ± 4.5%, P = 0.9). However, the coinfusion reduced energy intake compared with placebo (−30.4 ± 6.5%, P < 0.0001) and more than the sum of the monoinfusions ( P < 0.001), demonstrating a synergistic effect. Coinfusion slightly increased sensation of nausea ( P < 0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared with placebo (all P < 0.05); however, infusions of GLP-1 + PYY 3–36 resulted in an additional decrease compared with the monoinfusions (both P < 0.01). We conclude that coinfusion of GLP-1 and PYY 3–36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY 3–36 in combination compared with placebo. Coinfusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of these factors could explain the reduction in energy intake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 1×
“BARIATRIC SURGERY, particularly Roux-en-Y gastric bypass (RYGB), is currently the most effective treatment for severe obesity (2, 36, 37).”
BackgroundThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationA preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 4×
“Whereas GLP-1-mediated insulin secretion is supported by a substantial body of literature (21), both negative and no effects of PYY3–36 on insulin secretion have been reported (5, 42).”
BackgroundResultInfluentialon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“treatment (a GLP-1 analog) (3), as well as following PYY3–36 given at comparable doses (38).”
BackgroundSelf-citationHealth benefits of gastric bypass surgery after 6 years
Adams, T. D., Davidson, L. E., Litwin, S. E., Kolotkin, R. L., LaMonte, M. J., Pendleton, R. C., Strong, M. B., Vinik, R., Wanner, N. A., Hopkins, P. N., et al. (2012) · JAMA · doi:10.1001/2012.jama.11164 · Cited by 674
Barrachina, M. D., Martínez, V., Wang, L., Wei, J. Y., & Taché, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10455 · Cited by 440
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373 · cited 5×
“As recently reviewed, studies have shown that the shortterm administration of peptide YY (PYY)3–36 and glucagonlike peptide-1 (GLP-1) separately leads to a reduction in energy intake by mechanisms involving changes in central regulation of appetite (12).”
BackgroundResultInfluentialJacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Self-citation
Cited by
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Short-term (150 min) infusions of PYY alone reduce food ingestion in overweight human subjects, and further reductions are observed when PYY is co-infused with GLP-1 or oxyntomodulin [107,108].”
BackgroundTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss
Holst, J. J., Madsbad, S., Bojsen-Møller, K. N., Svane, M. S., Jørgensen, N. B., Dirksen, C., & Martinussen, C. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.03.003 · Cited by 202
Self-citationThe L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198
Svane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185
Self-citationThe role of higher protein diets in weight control and obesity-related comorbidities
Astrup, A., Raben, A., & Geiker, N. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.216 · Cited by 137
Self-citationGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“98), were greatly elevated after the operation and in particular after exendin 9–39 administration.”
Self-citationTan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
“5 hours) compared with previous studies employing shorter durations of 120 to 150 minutes (15, 16), indicating that this can potentially be given chronically for a sustained effect on energy intake and subsequent weight loss; and (3) the volunteers were fully ambulatory during the infusion, which is more in keeping wi…”
MethodResultSelf-citationTobore, T. O. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112560 · Cited by 73
Nielsen, M. S., Ritz, C., Wewer Albrechtsen, N. J., Holst, J. J., le Roux, C. W., & Sjödin, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa061 · Cited by 65
Self-citationCombination therapies for obesity
Camilleri, M., & Acosta, A. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0075 · Cited by 59
“4% of food intake compared to placebo and more than the sum of each independently, suggesting a synergistic effect.(12) A subsequent experimental study tested acute continuous subcutaneous infusion for 10.”
BackgroundTherapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“It is clear that other gut hormones, including PYY, may also play a role, which has prompted studies of combinations of the two hormones [118,119].”
BackgroundSelf-citationArciero, P., Edmonds, R., He, F., Ward, E., Gumpricht, E., Mohr, A., Ormsbee, M., & Astrup, A. (2016) · Nutrients · doi:10.3390/nu8080476 · Cited by 36
Self-citationCracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Sloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Metadata
- Authors
- Schmidt, J. B., Gregersen, N. T., Pedersen, S. D., Arentoft, J. L., Ritz, C., Schwartz, T. W., Holst, J. J., Astrup, A., & Sjödin, A.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2014-06-01
- Volume
- 306
- Issue
- 11
- Pages
- E1248-E1256
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W1987064421
- Cited by
- 146
- References
- 14
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.